This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

HCC Resources

Nexavar and Stivarga

Here you will find relevant materials related to Nexavar® (sorafenib) and Stivarga® (regorafenib) in HCC, as well as links to relevant articles and publications.

National Institute for Health and Care Excellence (NICE) guidance. Sorafenib for treating advanced hepatocellular carcinoma.

Download PDF

National Institute for Health and Care Excellence (NICE) guidance. Regorafenib for previously treated advanced hepatocellular carcinoma.

Download PDF

Scottish Medicines Consortium. Detailed advice on regorafenib 40mg film-coated tablets (Stivarga). SMC No 1316/18.

Download PDF

European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Download PDF
Nexavar Prescribing Information
Stivarga Prescribing Information
HCC Guidelines
PP-NEX-GB-0217, February 2024
Nexavar® (sorafenib) & Stivarga® (regorafenib)
In HCC
PP-NEX-GB-0224, March 2025
Tyrosine Kinase Inhibitors (TKI) Events & Webinars
PP-PF-ONC-GB-0412, February 2024

PP-NEX-GB-0215 | February 2024